Risk factors

Company faces clinical and regulatory hurdles for nascent allogeneic cell therapies requiring surgical delivery. R&D spending increased to $17.7 million in 2025.

YUTREPIA was FDA-approved in May 2025 and commercialized in June, shifting risk toward launch execution and uncertain demand.

Clinical and regulatory execution remains central: sotagliflozin HCM Phase 3, pilavapadin, and possible type 1 diabetes NDA resubmission.

Tax exposure now highlights OBBBA and Section 174 treatment of research expenses, including potential cash-flow effects.

Myers is pursuing a sale of its domestic and Central American Myers Tire Supply businesses, with transaction uncertainty and transition-service costs.

Profitability risk now emphasizes insufficient revenue growth or cost reductions compressing margins, replacing detailed executive compensation disclosures.

Nutex added substantial risk disclosures regarding the No Surprises Act, arbitration partner HaloMD lawsuits, short seller reports, and securities class actions. Former doctor owner share issuances, potential dilution, and valuation disputes dominate the new additions.

NextCure discloses a going concern warning with $41.8 million in cash insufficient for a year and an accumulated deficit of $436.0 million.

Okta added new risks addressing revenue growth reliance, customer support system breaches, international IP enforcement, and a $1 billion share repurchase program.

Strategic review initiated following stockholder agreement adds cost and distraction risks.

Customer concentration risks involving Amazon and Walmart were highlighted following commercial transaction agreements.

Palladyne AI expanded through November 2025 acquisitions of GuideTech, Warnke Precision Machining, and MKR Fabricators, introducing integration risks and defense industry manufacturing exposures.